Reviewing Integrated BioPharma (OTCMKTS:INBP) & Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ:ACRS) and Integrated BioPharma (OTCMKTS:INBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Insider and Institutional Ownership

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 25.3% of Integrated BioPharma shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 67.4% of Integrated BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aclaris Therapeutics and Integrated BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-900.01%	-39.73%	-27.98%
Integrated BioPharma	1.26%	3.32%	2.64%

Earnings and Valuation

This table compares Aclaris Therapeutics and Integrated BioPharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$18.72 million	20.49	-$132.07 million	($1.38)	-2.57
Integrated BioPharma	$54.35 million	0.19	$810,000.00	$0.01	34.00

Integrated BioPharma has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Aclaris Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Integrated BioPharma has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Aclaris Therapeutics and Integrated BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1	0	5	1	2.86
Integrated BioPharma	0	0	0	0	0.00

Aclaris Therapeutics currently has a consensus price target of $9.80, indicating a potential upside of 176.84%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Integrated BioPharma.

Summary

Integrated BioPharma beats Aclaris Therapeutics on 8 of the 15 factors compared between the two stocks.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.